Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A sustainable nutrition security intervention for low-income households

Principal Investigator: Yeary, Karen H

A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA…

Principal Investigator: Wong, Michael K

TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents

Principal Investigator: Green, Steven D

(AOST2032) A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Principal Investigator: Gupta, Ajay

EAY191-A6: A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY
ALTERATIONS

Principal Investigator: Levine, Ellis G

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary
Efficacy of BMS-986393 in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on…

Principal Investigator: Malek, Ehsan

A Phase 1 dose-escalation and expansion study to assess safety and preliminary antitumor activity of Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after previous…

Principal Investigator: Jain, Prantesh

A Phase I Clinical Trial Investigating Autologous CAR T cells Targeting GPC3 in Relapsed or Refractory Hepatocellular Carcinoma

Principal Investigator: Krishnamurthy, Anuradha

Influence of authorized smokeless tobacco product modified risk claims I: Consumer product demand

Principal Investigator: O'Connor, Richard J

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients with Advanced Cancer

Principal Investigator: Kabraji, Sheheryar K

(MCC 21704) A Multi-Institution Study of TGFb; imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination with Gemcitabine and Docetaxel in Patients with Relapsed or Refractory Pediatric Bone and Soft Tissue…

Principal Investigator: Gupta, Ajay

(ACNS1833) A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic…

Principal Investigator: Barth, Matthew J

A phase 1a/b study to evaluate the safety and efficacy of OPB-101, an autologous mesothelin (MSLN) CAR T cell therapy with antigen-dependent expression of OUTSMART designed IL-2 cytokine in platinum-resistant ovarian cancer

Principal Investigator: Zsiros, Emese

A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Autoimmune Disease (ADI-202300103)

Principal Investigator: Holtan, Shernan G

A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Principal Investigator: Malek, Ehsan

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers

Principal Investigator: Kabraji, Sheheryar K

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy …

Principal Investigator: Fitzgerald, Bailey

MyeloMATCH - Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials

Principal Investigator: Wang, Eunice S

MM1OA-S03: A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

Principal Investigator: Wang, Eunice S

MM1MDS-A01: A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study

Principal Investigator: Wang, Eunice S

MM1YA-CTG01: A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL

Principal Investigator: Wang, Eunice S

MM1OA-EA02: A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial

Principal Investigator: Wang, Eunice S

MM1YA-S01: A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax and Azacitidine + Venetoclax in Patients Aged 59 or Younger Who Are Considered High Risk …

Principal Investigator: Wang, Eunice S

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults with Relapsed or…

Principal Investigator: Wang, Eunice S

A032102: PRECISION DIAGNOSTICS IN PROSTATE CANCER TREATMENT (PREDICT)

Principal Investigator: Chatta, Gurkamal S